title: Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin.
abstract: OBJECTIVE
  To compare the efficacy, safety, and cost of prophylactic low-dose ganciclovir with that of immunoglobulin in renal transplant recipients at risk for primary cytomegalovirus (CMV) disease.
  
  
  METHODS
  A prospective, randomized trial at a 650-bed tertiary medical center hospital.
  
  
  METHODS
  Fifty-one consecutive CMV-seronegative patients who received renal allografts from seropositive donors between March 1990 and April 1992.
  
  
  METHODS
  Patient and allograft survival, and the incidence and severity of CMV disease.
  
  
  METHODS
  Cytomegalovirus prophylaxis with seven doses of intravenous immunoglobulin for 6-week periods (group 1, n = 27) or low-dose intravenous ganciclovir for 3 weeks (group 2, n = 24). Results were compared with those obtained in 23 CMV-seronegative historical controls who received renal allografts from CMV-seropositive donors between 1987 and 1989, and who did not receive prophylaxis for CMV (group 3).
  
  
  RESULTS
  Both prophylactic regimens significantly reduced the incidence of invasive CMV infection (P < .05) and were well tolerated. However, the cost of ganciclovir ($350 per patient) was substantially less than that of immunoglobulin ($4000 per patient).
  
  
  CONCLUSIONS
  These data suggest that prophylactic ganciclovir therapy provides a cost-effective approach toward significantly improving the outcome of renal transplantation in recipients at risk for primary CMV disease.
authors.affiliation: Department of Surgery, Albany Medical College, NY.
authors.forename: D J
authors.initials: DJ
authors.lastname: Conti
authors.forename: B M
authors.initials: BM
authors.lastname: Freed
authors.forename: S A
authors.initials: SA
authors.lastname: Gruber
authors.forename: N
authors.initials: N
authors.lastname: Lempert
mesh_terms: D000328:Adult; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D016527:Drug Costs; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000191:economics / Q000627:therapeutic use*; D006084:Graft Rejection / Q000209:etiology; D006085:Graft Survival; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use*; D015994:Incidence; D007262:Infusions, Intravenous; D016030:Kidney Transplantation; D007902:Length of Stay; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D016756:Immunoglobulins, Intravenous; D015774:Ganciclovir